ATA107397A - Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons - Google Patents

Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Info

Publication number
ATA107397A
ATA107397A AT107397A AT107397A ATA107397A AT A107397 A ATA107397 A AT A107397A AT 107397 A AT107397 A AT 107397A AT 107397 A AT107397 A AT 107397A AT A107397 A ATA107397 A AT A107397A
Authority
AT
Austria
Prior art keywords
cell clone
serum
protein
obtaining
free medium
Prior art date
Application number
AT107397A
Other languages
English (en)
Other versions
AT407255B (de
Inventor
Manfred Reiter
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3506017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA107397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT0107397A priority Critical patent/AT407255B/de
Application filed by Immuno Ag filed Critical Immuno Ag
Priority to US09/100,253 priority patent/US6100061A/en
Priority to US09/324,612 priority patent/US6475725B1/en
Publication of ATA107397A publication Critical patent/ATA107397A/de
Application granted granted Critical
Publication of AT407255B publication Critical patent/AT407255B/de
Priority to US10/170,661 priority patent/US6936441B2/en
Priority to US11/123,362 priority patent/US7094574B2/en
Priority to US11/482,504 priority patent/US20070161079A1/en
Priority to US12/488,465 priority patent/US8080414B2/en
Priority to US12/488,441 priority patent/US20090258391A1/en
Priority to US12/778,776 priority patent/US8084251B2/en
Priority to US12/848,897 priority patent/US8084252B2/en
Priority to US12/986,111 priority patent/US8329465B2/en
Priority to US14/567,942 priority patent/USRE46745E1/en
Priority to US15/203,558 priority patent/USRE46860E1/en
Priority to US15/203,550 priority patent/USRE46897E1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT0107397A 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons AT407255B (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US09/100,253 US6100061A (en) 1997-06-20 1998-06-19 Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US09/324,612 US6475725B1 (en) 1997-06-20 1999-06-02 Recombinant cell clones having increased stability and methods of making and using the same
US10/170,661 US6936441B2 (en) 1997-06-20 2002-06-12 Recombinant cell clones having increased stability and methods of making and using the same
US11/123,362 US7094574B2 (en) 1997-06-20 2005-05-06 Recombinant cell clones having increased stability and methods of making and using the same
US11/482,504 US20070161079A1 (en) 1997-06-20 2006-07-07 Recombinant cell clones having increased stability and methods of making and using the same
US12/488,465 US8080414B2 (en) 1997-06-20 2009-06-19 Recombinant cell clones having increased stability and methods of making and using the same
US12/488,441 US20090258391A1 (en) 1997-06-20 2009-06-19 Recombinant cell clones having increased stability and methods of making and using same
US12/778,776 US8084251B2 (en) 1997-06-20 2010-05-12 Recombinant cell clones having increased stability and methods of making and using the same
US12/848,897 US8084252B2 (en) 1997-06-20 2010-08-02 Recombinant cell clones having increased stability and methods of making and using the same
US12/986,111 US8329465B2 (en) 1997-06-20 2011-01-06 Recombinant cell clones having increased stability and methods of making and using the same
US14/567,942 USRE46745E1 (en) 1997-06-20 2014-12-11 Recombinant cell clones having increased stability and methods of making and using the same
US15/203,558 USRE46860E1 (en) 1997-06-20 2016-07-06 Recombinant cell clones having increased stability and methods of making and using the same
US15/203,550 USRE46897E1 (en) 1997-06-20 2016-07-06 Recombinant cell clones having increased stability and methods of making and using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Publications (2)

Publication Number Publication Date
ATA107397A true ATA107397A (de) 2000-06-15
AT407255B AT407255B (de) 2001-02-26

Family

ID=3506017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Country Status (2)

Country Link
US (1) US6100061A (de)
AT (1) AT407255B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
WO1998008934A1 (en) * 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
WO2002029083A2 (en) * 2000-10-02 2002-04-11 Novo Nordisk A/S Industrial-scale serum-free production of recombinant proteins in mammalian cells
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
US20040185534A1 (en) * 2000-10-02 2004-09-23 Knudsen Ida Molgaard Industrial-scale serum-free production of recombinant proteins in mammalian cells
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
EP1434857B1 (de) * 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Verfahren zur herstelllung rekombinanter proteine in eukaryontischen zellen
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
US6830917B2 (en) * 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
DK1499719T3 (da) * 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
JP3916516B2 (ja) * 2002-06-10 2007-05-16 独立行政法人科学技術振興機構 硬組織−軟組織界面再生用足場材料
CN101058800B (zh) 2002-07-09 2013-03-13 巴克斯特国际有限公司 用于细胞培养的无动物蛋白质培养基
PT1434858E (pt) * 2002-09-05 2008-07-28 Bavarian Nordic As Método de amplificação de um poxvírus em condições sem soro
CA2502162C (en) * 2002-09-30 2014-04-15 Maxygen Holdings Ltd. Fvii or fviia variants having increased clotting activity
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
ES2386010T3 (es) * 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
SI1644504T1 (sl) * 2003-06-19 2010-06-30 Bayer Healthcare Llc Variante Gla domene faktorja VII ali VIIa
CN1890257A (zh) * 2003-12-01 2007-01-03 诺和诺德医疗保健公司 液体因子ⅶ组合物的病毒过滤
CA2551026A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
RU2006138181A (ru) 2004-05-04 2008-06-10 Ново Нордиск Хелс Кеа Аг (Ch) О-связанные гликоформы полипептидов и способ их изготовления
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512097A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
BRPI0514984A (pt) 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1851305B1 (de) * 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Herstellung eines proteins in serumfreier zellkultur, die ein proteinhydrolysat aus pflanzen enthält
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
KR101423344B1 (ko) * 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
EP2423306A1 (de) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modifizierte Gerinnungsfaktor-IX-Polypeptide und deren Verwendung bei der Behandlung
JP5401446B2 (ja) 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
PT2235197T (pt) * 2007-12-27 2017-10-11 Baxalta Inc Processos para cultura de células
US20110014624A1 (en) * 2008-03-12 2011-01-20 Wyeth Llc Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins
HUE026210T2 (en) 2008-11-12 2016-05-30 Baxalta Inc Procedure for serum-free, insulin-free VII. factor
BR122021005965B1 (pt) 2009-07-31 2022-01-25 Baxalta Incorporated Método para produzir uma composição de desintegrina e metaloproteinase com motivo trombospondina (adamts)
US8623352B2 (en) 2009-09-21 2014-01-07 Baxter International Inc. Stabilized liquid and lyophilized ADAMTS13 formulations
IL286298B (en) 2010-07-08 2022-08-01 Baxalta Inc A method to generate high molecular weight substituted vwf in cell culture
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
CN103282042B (zh) 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
HUE035941T2 (en) 2011-08-02 2018-05-28 Baxalta GmbH Systems and Methods for Recombinant Production Methods to Increase Protein Yield
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
JP6742902B2 (ja) 2013-03-15 2020-08-19 ジェンザイム・コーポレーション 高密度細胞バンキングの方法
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6195191B2 (ja) * 2013-08-08 2017-09-13 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株を用いた組換えタンパク質の製造方法
JP6190205B2 (ja) * 2013-08-08 2017-08-30 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株、その製造方法及び培地
JP6760927B2 (ja) 2014-09-18 2020-09-23 ジェンザイム・コーポレーション 超高密度細胞バンキング方法
WO2021198781A2 (en) 2020-04-02 2021-10-07 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
DE69535940D1 (de) * 1994-11-10 2009-06-04 Baxter Healthcare Sa Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
AU703484B2 (en) * 1995-02-23 1999-03-25 Quest International Services B.V. Peptides for tissue and cell culture media
AUPN442295A0 (en) * 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells

Also Published As

Publication number Publication date
US6100061A (en) 2000-08-08
AT407255B (de) 2001-02-26

Similar Documents

Publication Publication Date Title
ATA107397A (de) Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
HUP9900995A3 (en) Artificial stone for stabilising traffic areas in the open
NO20001242D0 (no) April - et nytt protein med veksteffekter
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
HK1021388A1 (en) Ob fusion protein compositions and methods
DK0712862T3 (da) Selektiv acylering af epsilon-aminogrupper i insulin
DE69710487D1 (de) Stabiler standbeutel und verfahren zur herstellung
DK0802941T3 (da) Biologisk nedbrydelige polymerer, fremgangsmåde til fremstilling deraf, samt deres anvendelse til fremstilling af biologisk
DE69631796D1 (de) Verfahren und zusammensetzung zur reduktion der säure in kaffee
DK0809666T4 (da) Biologisk nedbrydelige polymerer, fremgangsmåder til deres fremstilling samt deres anvendelse til fremstilling af bionedbrydelige formlegemer
GB2315752A8 (en) Heat stable anti-freeze proteins
DE69901178D1 (de) Nichtgesinterte elektrode und verfahren zur herstellung
DE69815789D1 (de) Kniegelenkendprothese mit verbesserter hinterer Stabilität und Massnahmen zur Verhinderung einer Dislokation
DE59915087D1 (de) Verfahren zur kontrolle von schadorganismen in kulturen von bt-baumwolle
DE69940205D1 (de) Variable seitenzusammensetzung mit zerteilung der seitenelemente in streifen
ZA988921B (en) 3,4-diarylthiazolin-2-one or -2-thione derivatives their methods of preparation and their uses in therapeutics
NO992693D0 (no) Celledelt radiosystem med forbedrede egenskaper i grenseomrÕder
EP0980202A4 (de) Verfahren zur viralen inaktivierung und darin verwendbare zusammensetzungen
DE59900960D1 (de) Latentwärmekörper mit porenstruktur und verfahren zu dessen herstellung
DE19981016D2 (de) Diamantbauelement mit Rückseitenkontaktierung und Verfahren zu seiner Herstellung
AU4910299A (en) Gene and protein involved in liver regeneration
DE59805666D1 (de) Aliphatische Alkanale mit verbesserter Lagerstabilität und Verfahren zur Verbesserung der Lagerstabilität
DE59800919D1 (de) Haardauerverformungsverfahren mit zunächst höherem und später niedrigerem pH-Wert in der Reduktionsstufe
PL327224A1 (en) Ready-to-cook dish in the form of solid body, method of preparing same and system therefor
SI1121382T1 (sl) Fuzijski proteini interferona-beta in uporabe

Legal Events

Date Code Title Description
MK07 Expiry

Effective date: 20170620